UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 


 

FORM 8-K

 


 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported):  March 19, 2008

 


 

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

000-30319

 

94-3265960

(State or Other Jurisdiction of

 

(Commission File Number)

 

(I.R.S. Employer Identification Number)

Incorporation)

 

 

 

 

 

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 7.01 Regulation FD Disclosure.

 

The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Today at the International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium, Professor Antoni Torres of the Hospital Clinic de Barcelona will present data from Theravance’s ATLAS and ATTAIN programs. Those of Professor Torres’ slides containing information regarding telavancin have been excerpted and are attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

ITEM 9.01 Financial Statements and Exhibits.

 

 

(d)

Exhibits

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit

 

Description

 

 

 

 

 

 

 

Exhibit 99.1

 

Excerpt of presentation slides

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

THERAVANCE, INC.

 

 

 

Date: March 19, 2008

 

By:

/s/ Michael W. Aguiar

 

 

Michael W. Aguiar

 

 

Chief Financial Officer

 

3



 

EXHIBIT INDEX

 

Exhibit No.

 

Exhibit

99.1

 

Excerpt of presentation slides

 

4


Exhibit 99.1

 

GRAPHIC

Telavancin • A novel rapidly bactericidal lipoglycopeptide • Unique multifunctional mechanism of action – inhibition of bacterial cell wall synthesis – depolarization of the bacterial membrane • Active against clinically relevant Gram-positive pathogens including strains resistant to other Gram-positive agents • At least as efficacious as vancomycin in patients with complicated skin and soft tissue infections caused by MRSA • Exceptional intracellular and extracellular activity • Good penetration into pulmonary fluids and alveolar macrophages

 


GRAPHIC

Telavancin spectrum of Gram-positive activity 0.12 0.03 <0.015–1 169 - Viridans strep 0.03 0.015 <0.001–0.06 455 All† S. pneumoniae 0.06 0.06 <0.001–0.12 99 - S. agalactiae 0.06 0.03 0.015–0.12 122 - S. pyogenes 1 0.5 0.06–1 855 VSE E. faecalis 0.25 0.12 <0.015–1 368 VSE E. faecium 0.25 0.25 0.06–1 1313 MRSA 0.5 0.25 0.03–1 1491 MSSA S. aureus MIC90 MIC50 Range Total Phenotype Organism Telavancin MIC (µg/ml) † PSSP, PRSP, Macrolide-resistant VSE=vancomycin susceptible enterococci MIC=minimum inhibitory concentration 2004–2005 Telavancin US and Europe Surveillance (Focus Bio-Inova). Data on file.

 


GRAPHIC

Comparative activity of telavancin against MRSA Daptomycin Susceptibility of MRSA (N=1629) <0.5 – >4 2 0.5 – 4 1 0.12 – >1 1 0.06 – 1 0.5 Range 90% MIC (µg/mL) 0.03 0.06 0.12 0.25 0.5 1 2 4 8 0 20 40 60 80 100 Telavancin Vancomycin Linezolid MIC (µg/ml) Cumulative % at MIC 2005 Telavancin US and Europe Surveillance (Focus Bio-Inova). Data on file.

 


GRAPHIC

Telavancin retains potent activity against S. aureus with reduced susceptibility to other agents 1 1 1 2 1 1 1 1 1 1 2 1 1 MIC MIC µg/ml µg/ml VAN VAN NS >4 S 0.5 0.12 S. aureus NS >4 S 0.5 0.12 S. aureus NS >4 S 0.5 0.12 S. aureus NS >4 S 0.5 0.06 S. aureus S 1 NS >1 0.25 S. aureus S 2 NS >1 0.5 S. aureus S 1 NS >1 0.5 S. aureus >4 >4 >4 >4 >4 1 MIC MIC µg/ml µg/ml LZD LZD NS NS NS NS NS S CLSI* CLSI* S S S S S NS CLSI* CLSI* 0.5 0.5 0.5 0.5 0.5 >1 MIC MIC µg/ml µg/ml DAP DAP 0.5 0.25 0.25 0.25 0.25 0.5 MIC MIC µg/ml µg/ml TLV TLV S. aureus S. aureus S. aureus S. aureus S. aureus S. aureus Organism Organism Draghi DC, et al. ICAAC 2006. Poster E-0715. Activity of TLV vs S. aureus not susceptible to DAP or LZD *CLSI M100-S15 (2005) breakpoints utilized to interpret isolates as susceptible (S), intermediately susceptible (I), resistant (R), or nonsusceptible (NS).

 


GRAPHIC

60-min IV infusion of 10 mg/kg once daily for 3 days • Telavancin was present in ELF at pharmacologically relevant concentrations for the entire dosing interval (24 h) Telavancin concentrations in plasma, alveolar macrophages (AM) and epithelial lining fluid (ELF) 0 5 10 15 20 25 0.1 1 10 100 1000 Plasma AM ELF Time (h) Telavancin Concentration (µg/mL) MIC90 Cmax (ELF), 3.73 µg/ml at 8 h Cmax (plasma), 116 µg/ml at 1 h Cmax (AM), 45 µg/ml at 12 h Gotfried M. ICAAC 2005. Poster A-14.

 


GRAPHIC

Telavancin concentration in alveolar macrophages (AM) and epithelial lining fluid (ELF) from BAL Samples Gotfried M. ICAAC 2005. Poster A-14. Mean Ratios of ELF and AM Concentrations to MIC90 for Staphylococcus aureus at the 4 BAL Sampling Times ELF/MIC ELF/MIC90 90 AM/MIC AM/MIC90 90 0 25 50 75 100 4 8 12 24 Time (h) Concentration Ratio 0 2 4 6 8 10 4 8 12 24 Time (h) Concentration Ratio

 


GRAPHIC

Telavancin clinical programme • Indications studied: cSSTI and HAP – Two large, methodologically identical, double-blind, multicentre, multinational, randomised, active controlled studies to evaluate the efficacy and safety of telavancin in each indication • Large patient populations – No upper age limit – Included moderate and severe renal impairment in contrast to other registrational programs excluding renal impairment • Focus on MRSA – Community- and hospital-acquired MRSA – Largest registrational trial experience of MRSA infections to date

 


GRAPHIC

Corey R, et al. IDSA 2006. Poster LB-17. ATLAS phase 3 cSSTI: conclusions • Telavancin was shown to be as effective as vancomycin for the treatment of cSSTI • The telavancin safety profile was compatible with treatment of serious Gram-positive infections due to resistant bacteria • These data support the efficacy and safety of once-daily telavancin in the treatment of Gram-positive cSSTI

 


GRAPHIC

The ATTAIN programme: ATTAIN 1 & 2 • Two large, methodologically identical, double-blind, multicentre, multinational, randomised, active controlled studies to evaluate the efficacy and safety of telavancin versus vancomycin for treatment of hospital-acquired pneumonia due to Gram-positive bacteria • Primary endpoint – non-inferiority in clinical cure at test-of-cure (TOC) visit in the all-treated (AT) and clinically evaluable (CE) populations • Study population – 1503 patients treated in 38 countries – 464 with MRSA identified at baseline culture

 


GRAPHIC

Key patient inclusion and exclusion criteria Inclusion: • Male and female patients > 18 years old • Clinical signs and symptoms of pneumonia acquired after > 48 hours of hospitalisation OR acquired < 7 days after discharge from > 3 days of hospitalisation • Diagnosis of pneumonia by chest radiograph < 48 hours prior to randomisation • Respiratory or sputum specimens for Gram-staining and culture available • Patients with renal impairment, including patients on hemodialysis were not excluded Exclusion: • > 24 hours potentially effective antibiotic therapy – known infection with MSSA or S. pneumoniae AND required concomitant therapy for Gram-positives > 24 hours active against either of these • Respiratory specimen with only Gram-negative bacteria on Gram stain or culture • Legionella pneumophilia pneumonia, meningitis, infectious endocarditis or osteomyelitis • Neutropenia

 


GRAPHIC

Treatment regimen • Randomisation (1:1) to – Telavancin 10 mg/kg IV q24h – Vancomycin 1 g IV q12h ¦ dosing optimisation allowed per individual site guidelines ¦ switching to antistaphylococcal penicillin allowed for MSSA infections • Study treatment for 7–21 days ¦ concomitant aztreonam and/or metronidazole permitted for patients with confirmed or suspected polymicrobial infections ¦ piperacillin-tazobactam or imipenem may be administered for Gram-negative coverage only if aztreonam is not appropriate due to resistance issues • Follow-up for test-of-cure 7–14 days after end of study treatment

 


GRAPHIC

Demographic and baseline characteristics 28% 29% VAP 46% 46% Ventilated 14% / 3% 13% / 3% Obese / morbidly obese 71 kg 72 kg Mean weight 22% 23% Diabetic 31% 31% Age 75 yr or greater 54% 53% Age 65 yr or greater 63 yr 62 yr Mean age 62 : 38 65 : 35 Male : Female 21 : 79 24 : 76 US : Non-US Vancomycin n = 754 Telavancin n = 749

 


GRAPHIC

Clinical response Clinical cure at TOC in CE population and in subpopulations VAP 1.8 (–4.1, 7.7) 80.9% 82.7% Clinically evaluable 88.4% 75.5% 84.2% 67.6% 74.1% Vancomycin 1.9 (–5.4, 9.3) 90.3% Non-ICU pneumonia 13.2 (–1.8, 26.8) 80.3% Yes –0.8 (–7.2, 5.6) 83.4% No 2.2 (–6.3, 10.7) 77.7 % ICU pneumonia ICU location at baseline 8.1%, (–3.3, 19.4) 82.0% MRSA pneumonia Difference,% (95% CI) Telavancin

 


GRAPHIC

Overview of adverse events 8% 10% Renal adverse events 7% 8% QTc > 60 ms prolongation 2% 2% QTc interval > 500 ms 9% 9% Constipation 11% 9% Anemia 12% 11% Diarrhea Most frequent treatment emergent adverse events 81% 82% At least 1 AE Vancomycin Telavancin

 


GRAPHIC

Conclusions Telavancin in HAP Phase 3 programme • Study met primary endpoint – non-inferiority attained in AT and CE populations in both studies, 95% CIs well within 10% margin • Numerical trends favouring telavancin in subpopulations of patients with severe disease – VAP, MRSA • Safety profile compatible with treatment of serious Gram-positive infections